Welcome to our dedicated page for Scisparc SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SciSparc Ltd. (Nasdaq: SPRC) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. SciSparc files annual reports on Form 20-F and frequent current reports on Form 6-K, which together describe its clinical-stage pharmaceutical activities, capital structure, and material corporate events.
Recent Form 6-K filings highlight several categories of information. Transaction-related 6-Ks describe agreements such as the asset and share purchase arrangement through which SciSparc obtained a controlling interest in NeuroThera Labs Inc. and transferred its advanced clinical-stage pharmaceutical portfolio and its stake in SciSparc Nutraceuticals Inc. to NeuroThera. Other 6-Ks detail the sale of MitoCareX Bio Ltd. to N2OFF, Inc., the binding term sheet and definitive agreement to acquire a treasury of patents and trademarks for the MUSE endoscopic system from Xylo Technologies Ltd., and a framework agreement terminating a prior merger agreement with AutoMax Motors Ltd. and setting loan repayment terms.
Filings also cover capital markets and compliance matters, including inducement letter agreements with holders of existing warrants, under which warrant exercise prices were adjusted and SciSparc expects to receive gross proceeds for working capital and general corporate purposes. Another 6-K reports a Nasdaq notification that the company no longer met the minimum stockholders’ equity requirement for continued listing, and outlines the timeframe to submit a compliance plan.
In addition, SciSparc uses Form 6-K to furnish financial statements and MD&A, such as unaudited consolidated interim financial statements and management’s discussion and analysis for the six months ended June 30, 2025. Patent- and R&D-related press releases—covering NeuroThera’s opioid–N-acylethanolamine patent, MEAI-based depression patent applications, and the quantum computing-enabled 3D protein modeling initiative—are also incorporated by reference via 6-K exhibits.
On this page, users can review SciSparc’s 6-K submissions, including exhibits like binding term sheets, asset and share purchase agreements, and inducement letters, alongside its 20-F annual report. AI-powered tools summarize key points from these filings, highlight items such as equity transactions, IP acquisitions, and listing status updates, and help readers navigate complex transaction terms and risk disclosures without reading every page in detail.
SciSparc Ltd. director Shrem Itschak filed an initial ownership report showing his equity position in the company. He directly holds 11,058 Ordinary Shares and a stock option to buy 6 Ordinary Shares at an exercise price of 21294.0000 per share, expiring on March 1, 2028.
The filing also notes restricted share units. These include 10,000 Ordinary Shares in RSUs vesting in equal quarterly installments of 1,250 shares beginning on March 18, 2026, and 396 Ordinary Shares in RSUs vesting 50 shares quarterly beginning on September 30, 2024. Each RSU converts into one Ordinary Share when vested.
SciSparc Ltd. director Shay Amnon Ben filed an initial Form 3 reporting his beneficial ownership in the company. He directly holds 3,651 Ordinary Shares. This amount includes 3,333 Ordinary Shares issuable from restricted share units vesting in equal quarterly installments of 417 shares beginning on March 18, 2026, and 120 Ordinary Shares issuable from RSUs vesting in equal quarterly installments of 15 shares beginning on September 30, 2024, with each RSU converting into one Ordinary Share.
He also holds a stock option for 1 Ordinary Share at an exercise price of 21,294.0000 that became fully vested on April 21, 2024 and expires on March 1, 2028. The filing does not reflect any buy or sell transactions, only current holdings and award structures.
SciSparc Ltd. director Revach Moshe filed an initial ownership report showing direct holdings of 3,651 Ordinary Shares and stock options over 1 Ordinary Share that are fully vested as of April 21, 2024.
The filing also notes future equity rights from restricted share units. These include 3,333 Ordinary Shares vesting in equal quarterly installments of 417 shares beginning on March 18, 2026, and 120 Ordinary Shares vesting in equal quarterly installments of 15 shares beginning on September 30, 2024, with each RSU delivering one Ordinary Share at vesting.
SciSparc Ltd. CEO and CFO Adler Oz filed a Form 3 reporting his equity holdings in the company. He directly holds 11,058 Ordinary Shares. He also holds a stock option covering 6 Ordinary Shares at an exercise price of 21294.0000, which is fully vested and expires on March 1, 2028.
The filing notes additional equity that may be received through restricted share units. These RSUs cover 10,000 Ordinary Shares vesting in equal quarterly installments of 1,250 shares beginning on March 18, 2026, and 396 Ordinary Shares vesting in equal quarterly installments of 50 shares beginning on September 30, 2024. Each RSU entitles him to receive one Ordinary Share.
SciSparc Ltd. director Weiss Amitay reported initial holdings of 11,058 Ordinary Shares, held directly. This amount includes 10,000 Ordinary Shares issuable from restricted share units vesting in equal quarterly installments of 1,250 shares beginning on March 18, 2026, and 396 Ordinary Shares from restricted share units vesting in equal quarterly installments of 50 shares beginning on September 30, 2024. Amitay also holds a stock option, fully vested on April 21, 2024, to acquire 6 Ordinary Shares at an exercise price of 21294.0000 per share, expiring on March 1, 2028.
SciSparc Ltd. director Vider Lior has reported initial ownership holdings. The filing shows direct holdings of 3,651 Ordinary Shares and a stock option for 1 Ordinary Share with an exercise price of 21,294.0000, expiring on March 1, 2028 and fully vested on April 21, 2024.
The footnotes explain additional equity incentives through restricted share units. These cover 3,333 Ordinary Shares vesting in equal quarterly installments of 417 shares beginning on March 18, 2026, and 120 Ordinary Shares vesting in equal quarterly installments of 15 shares beginning on September 30, 2024, with each RSU representing one Ordinary Share.
SciSparc Ltd. Chief Technology Officer Adi Zuloff-Shani filed an initial ownership report detailing current equity interests. The filing shows direct beneficial ownership of 5,528 Ordinary Shares, which includes 5,198 shares subject to restricted share units that vest in scheduled quarterly installments.
The report also lists a fully vested stock option to acquire 6 additional Ordinary Shares at an exercise price of 21,294.0000 per share, expiring on March 1, 2028. This Form 3 is a disclosure of existing holdings and compensation awards, not a report of new share purchases or sales.
SciSparc Ltd. director Liat Sidi filed an initial ownership report, disclosing direct holdings of 3,651 Ordinary Shares. This figure includes 3,333 Ordinary Shares issuable from restricted share units (RSUs) vesting in equal quarterly installments of 417 shares beginning on March 18, 2026, and 120 Ordinary Shares issuable from RSUs vesting in equal quarterly installments of 15 shares beginning on September 30, 2024. Each RSU represents the right to receive one Ordinary Share. The filing also notes a fully vested stock option to buy 1 Ordinary Share at an exercise price of 21,294, expiring on March 1, 2028.
SciSparc Ltd. reports a Schedule 13G filing: Ronen Fatal discloses beneficial ownership of 5% or less of the companys Ordinary Shares as of
The filing lists the reporting person as Ronen Fatal, citizenship Israel, and gives his business/residence address in Ramat Gan. The cover references items 5-11 for exact beneficial ownership and dispositive power details. The form is signed on
SciSparc Ltd. filing: Eli Zamir submitted a Schedule 13G reporting beneficial ownership of 5 percent or less of a class of Ordinary Shares as of 12/31/2025. The cover pages are incorporated by reference and the form is signed on 03/16/2026.